Dr. Plimack on Second-Line Checkpoint Inhibitors in Bladder Cancer

Elizabeth Plimack, MD
Published: Tuesday, Dec 12, 2017



Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

In 2017, the FDA approved nivolumab (Opdivo), durvalumab (Imfinzi), avelumab (Bavencio), and pembrolizumab (Keytruda) for the second-line treatment of patients with bladder cancer. These drugs join previously approved atezolizumab (Tecentriq).

It is hard to differentiate between these 5 regimens, says Plimack, as there are no randomized trials comparing them in this setting.
 


Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

In 2017, the FDA approved nivolumab (Opdivo), durvalumab (Imfinzi), avelumab (Bavencio), and pembrolizumab (Keytruda) for the second-line treatment of patients with bladder cancer. These drugs join previously approved atezolizumab (Tecentriq).

It is hard to differentiate between these 5 regimens, says Plimack, as there are no randomized trials comparing them in this setting.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x